CD274 and melanoma: Tumor PD‐L1 (B7‐H1) expression, measured by immunohistochemistry, has been shown to be a predictive biomarker of the response to anti‐PD‐L1 therapy, especially in melanoma and non‐small‐cell lung cancer.96